On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). Participants from more than 25 countries, representing 28 medicines regulatory authorities globally and experts from the World Health Organization and the European Commission discussed the available knowledge on possible treatments (drugs and biologics) for COVID-19, including:
- Progress on COVID-19 medicine development
- Availability of potential COVID-19 treatments
- Ongoing and planned clinical trials
- Compassionate use and off-label use of medicines in the context of COVID-19
The goal of the meeting was to exchange information about the progress made on the development of potential COVID-19 therapeutics and to reaffirm the need for large clinical trials, which are most likely to generate the conclusive evidence needed to enable faster development and approval of treatments for COVID-19…